期刊文献+

西格列汀治疗老年2型糖尿病患者的临床观察 被引量:9

下载PDF
导出
摘要 老年2型糖尿病患者的治疗相对于年轻糖尿病患者有很多特点:①老年糖尿病患者的脏器功能减退,往往有很多的合并症及并发症,导致了口服降糖药的选择面缩小,如肾功能不全禁用二甲双胍,心功能不全禁用胰岛素增敏剂,部分患者出现了继发性磺脲类失效等;②胰岛素注射技术、饮食运动治疗的配合、血糖的监测等方面知识的掌握对老年患者而言均是难题,要求使用顺应性好、疗效确切的药物;③老年患者对低血糖反应性差,如果发生低血糖则危害更大,需要使用低血糖发生率低、安全性好的药物。近年来出现的二肽基肽酶-4(DPP-4)抑制剂为老年糖尿病患者提供了一种较为理想的选择。近来我们观察了磷酸西格列汀片治疗老年2型糖尿病疗效及安全性,报告如下。
出处 《中国药物与临床》 CAS 2012年第3期375-376,共2页 Chinese Remedies & Clinics
  • 相关文献

参考文献4

  • 1Charbonnel B,Karasik A,Liu J,et al.Efficacy and safety of the dipeptidyl peptidase-4inhibitor sitagliptin added to ongoing met-formin therapy in patients with type2diabetes inadequately controlled with metformin alone.Diabetes Care,2006,29(12):2638-2643. 被引量:1
  • 2Ahrén B.Use of DPP-4inhibitors in type2diabetes:focus on sitagliptin.Diabetes Metab Syndr Obes,2010,3:31-41. 被引量:1
  • 3Williams-Herman D,Engel SS,Round E,et al.Safety and tolera-bility of sitagliptin in clinical studies:a pooled analysis of data from10246patients with type2diabetes.BMC Endocr Disord,2010,10:7. 被引量:1
  • 4Mohan V,Yang W,Son HY,et al.Efficacy and safety of sitagliptin in the treatment of patients with type2diabetes in China,India,and Korea.Diabetes Res Clin Pract,2009,83(1):106-116. 被引量:1

同被引文献55

  • 1姜文清,杨莉萍,马捷,邹定,李金娥.长效基础胰岛素类似物甘精胰岛素[J].中国新药杂志,2005,14(6):778-781. 被引量:61
  • 2王志耀.内科学[M].北京:人民卫生出版社,2005,984-986. 被引量:17
  • 3Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabe- tes [J]. Diabetes Res Clin Pract ,2008,79 (2):291-298. 被引量:1
  • 4Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase4 inhibitor, sitagliptin in patients with type 2 diabetes mellitus inadequately controlled on glimepifide alone or on glimepiride and metformin [ J ]. Diabetes Obes Metab ,2007,9(5 ) :733-745. 被引量:1
  • 5贾伟平.GLP·1及其类似物与6细胞保护[N].中国医学论坛报(循环专刊),2010. 被引量:1
  • 6Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin : a retrospective ob- servational pharmacy claims analysis[J]. Diabetes Care,2010, 33 ( 11 ) :2349-2354. 被引量:1
  • 7Mohan V, Yang W, Son HY, et al. Efficacy and safety of sita- gliptin in the treatment of patients with type 2 diabetes in China, India, and Korea [J]. Diabetes Res Clin Pract, 2009,83 (1) :106-116. 被引量:1
  • 8Xu L, Man CD, Charbonnel B, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach [ J ]. Diabetes ObesMetab ,2008,10 ( 12 ) : 1212-1220. 被引量:1
  • 9Rasmussen H B, Branner S,Wiberg F C,et al. Crystal structure of human dipeptidyl peptidase 1V/CD26 in complex with a substrate analog[ J]. Nat Struct Biol,2003,10( 1 ) :19. 被引量:1
  • 10Aschner P,Kipnes M S,Lunceford J K,et al. Effect of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [ J 1. Diabetes Care ,2006,29 ( 12 ) :2632. 被引量:1

引证文献9

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部